OpenAI Researcher Miles Wang Jumps to Biotech AI Startup Valued at $2 Billion

OpenAI researcher Miles Wang is leaving the company to launch an AI drug discovery startup that has already reached a $2 billion valuation, according to reports from TechCrunch and ShortSingh. He is in talks to raise approximately $200 million, with Lightspeed Venture Partners potentially leading the funding round, TechCrunch reported.

ShortSinghOpenAI Researcher in Talks to Launch AI Drug Discovery Startup at $2B Valuation

The new venture will focus on developing AI models for drug discovery, particularly repurposing failed pharmaceutical drugs, according to startupfortune.com. TechCrunch noted that several other OpenAI researchers are expected to join the company.

startupfortune.comOpenAI Researcher Miles Wang Raises $200 Million for AI Drug Discovery Startup

"The high valuation reflects a broader venture capital shift from general AI demos toward specialized AI applications that could transform drug development economics."

This shift underscores a growing investor appetite for targeted AI solutions that can deliver concrete results in drug development, moving beyond the general-purpose AI hype.

Wang, a Harvard dropout, is leveraging his background to build a startup that could reshape how drug candidates are identified, startupfortune.com reported. The $2 billion valuation for a pre-revenue company highlights the premium placed on top-tier AI talent entering the biotech space.

"The development signals growing investor interest in applying artificial intelligence to pharmaceutical research and development."

That interest is now translating into concrete capital commitments, with Lightspeed's involvement marking another major bet on AI-driven drug discovery, a sector that has attracted significant funding in recent months. According to TechCrunch and ShortSingh, Wang's startup is still in the formation stage, and neither OpenAI nor Wang have issued official statements.